Recurrent vulvar cancer presents unique challenges for patients and healthcare teams alike, requiring carefully tailored treatment approaches that take into account where the cancer has returned, how far it has spread, and what treatments were used before.

Managing a Return of Cancer: Treatment Goals and Challenges

When vulvar cancer comes back after initial treatment, it brings a new set of decisions and treatment considerations. Recurrent vulvar cancer means that cancer has returned after a period when it seemed to be gone. This happens in approximately 24% of patients who had initial treatment with surgery, with or without radiation^[1][9]. The main goal of treating recurrent vulvar cancer is to control the disease, relieve symptoms, maintain quality of life, and when possible, extend survival.

Treatment decisions depend heavily on several important factors. Where the cancer has returned matters significantly—whether it’s in the vulva itself, nearby lymph nodes, or has spread to distant organs. The size and location of the recurrent tumor influence which treatments can be safely used. Another critical consideration is whether radiation therapy was part of the first treatment, as this may limit how much additional radiation can be given to the same area^[3][8][18].

Because vulvar cancer itself is quite rare—with only about 6,500 new cases diagnosed in the United States each year—and recurrences represent an even smaller number, it has been difficult for researchers to conduct large randomized studies that would clearly establish the best treatment approaches^[1][6][9]. Most of what doctors know about treating recurrent vulvar cancer comes from smaller studies and accumulated clinical experience. This means treatment must be highly individualized, with the healthcare team carefully weighing the potential benefits and risks for each patient.

Standard Treatment Approaches for Recurrent Vulvar Cancer

Surgery as the Foundation of Treatment

Surgery has traditionally been and continues to be the most widely accepted treatment for recurrent vulvar cancer^[1][9]. When cancer returns in a localized area and hasn’t spread extensively, surgical removal may offer the best chance for long-term control. The type of surgery recommended depends on several factors, including how deep the tumor has grown, its size, and precisely where it’s located in the vulva^[3][8][18].

For some recurrences, a complete radical vulvectomy may be necessary. This extensive operation removes the entire vulva, including the clitoris, the deeper tissues beneath the vulvar skin, and nearby lymph nodes^[3][8][18]. While this is major surgery with significant impact on the body, it may be the most effective option when cancer has returned to a larger area of the vulva.

In more extensive cases, particularly when cancer has come back in the pelvis, doctors may recommend a pelvic exenteration. This is one of the most major operations in gynecologic oncology. It involves removing the vulva and groin lymph nodes, along with one or more pelvic organs such as the vagina, uterus, bladder, or rectum^{[3][8][14][18]}. This surgery is typically reserved for local recurrence in the pelvis where cancer hasn’t spread to distant parts of the body. Recovery from pelvic exenteration is lengthy and requires significant physical and emotional adjustment. Patients may need reconstructive surgery and will often require permanent changes such as colostomies or urostomies, depending on which organs were removed.

After major surgery, hospital stays of several days are common. Patients may be discharged with surgical drains in place, which need care for several weeks. Some patients require consultation with plastic surgeons if a large area of skin needs to be removed and reconstructed^[12]. The decision to proceed with major surgery must balance the potential for disease control against the impact on quality of life and bodily function.

Radiation Therapy in Recurrent Disease

Radiation therapy uses high-energy rays or particles to destroy cancer cells. For recurrent vulvar cancer, radiation may be used in several different ways depending on the clinical situation^[3][8][18].

External beam radiation therapy directs radiation at the tumor from outside the body. It may be given with or without chemotherapy. When used before surgery, this is called neoadjuvant therapy—the goal is to shrink the tumor to make surgical removal easier or more complete^[3][8][18]. External radiation can also serve as palliative therapy, meaning it’s used to relieve pain or control symptoms of recurrent vulvar cancer even when cure is not the primary goal.

Brachytherapy is a specialized type of internal radiation therapy. A sealed container holding radioactive material is placed inside the body, either directly into the tumor or very close to it. This allows doctors to deliver a high dose of radiation directly to the cancer while limiting exposure to surrounding healthy tissues. Brachytherapy is sometimes used alongside external radiation to boost the total radiation dose to the tumor^[3][8][18].

An important limitation is that radiation to the same area cannot be repeated indefinitely. If a patient already received radiation as part of their initial vulvar cancer treatment, there may be restrictions on how much additional radiation can safely be given to that region without causing serious damage to healthy tissues. This is why the treatment history plays such a crucial role in planning for recurrent disease.

Side effects of radiation therapy can include skin changes, fatigue, and discomfort in the treated area. The vulvar skin may become red, irritated, or develop sores. These effects usually improve after treatment ends, though some changes may be long-lasting. Radiation can also affect sexual function and may cause scarring or narrowing of the vagina if it’s in the treatment field.

Chemotherapy for Recurrence

Chemotherapy involves using drugs that travel through the bloodstream to destroy cancer cells throughout the body. For recurrent vulvar cancer, chemotherapy is often given together with radiation therapy rather than alone^[3][8][18].

When chemotherapy and radiation are given during the same time period, this combination is called chemoradiation. The chemotherapy can make the cancer cells more sensitive to radiation, potentially making the treatment more effective. Chemoradiation may be offered to patients who cannot undergo surgery because of other health problems or when the tumor extends into areas that would be very difficult to remove surgically^[3][8][18].

The most commonly used chemotherapy drugs for vulvar cancer in this setting include cisplatin combined with paclitaxel, or alternatively carboplatin with paclitaxel^[3][8][18]. Cisplatin and carboplatin are platinum-based drugs that interfere with cancer cell DNA, preventing the cells from dividing. Paclitaxel works by disrupting the internal structure that cells need to divide and grow.

Chemotherapy can also be used alone as palliative chemotherapy when cancer has spread widely. In this situation, the goal is to relieve pain and control symptoms of advanced disease, helping to maintain quality of life even when curing the cancer is not possible^[3][8][18].

Side effects of chemotherapy vary depending on which drugs are used, but commonly include fatigue, nausea, hair loss, lowered blood cell counts that increase infection risk, numbness or tingling in hands and feet (called peripheral neuropathy), and changes in taste or appetite. Your medical team will monitor you closely during chemotherapy and can provide medications and support to help manage side effects.

Targeted Therapy: A Newer Approach

Targeted therapy represents a more recent addition to treatment options for recurrent vulvar cancer. Unlike traditional chemotherapy, which affects all rapidly dividing cells, targeted therapy drugs are designed to attack specific molecules—such as particular proteins—on or inside cancer cells. By focusing on these specific targets, these drugs may interfere with cancer growth and spread while potentially causing fewer side effects than conventional chemotherapy^[3][8][18].

Two targeted therapy drugs have been used for recurrent vulvar cancer. Bevacizumab (sold under the brand name Avastin, and also available as biosimilars) works by blocking a protein called VEGF, which cancer cells use to stimulate the growth of new blood vessels. By cutting off the blood supply that feeds the tumor, bevacizumab may slow cancer growth. Erlotinib (brand name Tarceva) targets a different protein called EGFR, which is involved in cell growth and division^[3][8][18].

Sometimes a targeted therapy drug is combined with a chemotherapy drug, with the idea that the two approaches together may be more effective than either alone. It’s important to note that targeted therapy drugs used for vulvar cancer may not be covered by all provincial and territorial health plans or insurance providers. Patients should discuss coverage and potential out-of-pocket costs with their healthcare team and insurance company before starting treatment^[3][8][18].

Treatment Approaches Being Tested in Clinical Trials

Because recurrent vulvar cancer remains challenging to treat and affects a relatively small number of patients, researchers continue to explore new treatment approaches through clinical trials. However, the rarity of this cancer has made it difficult to conduct large-scale studies specifically focused on recurrent vulvar cancer^[1][9].

Clinical trials for recurrent vulvar cancer often build on the promising results seen with combined approaches. Recent years have brought new emphasis on chemoradiation—the combination of radiation therapy with chemotherapy—which has shown very encouraging results^[1][9]. While this combination is now becoming part of standard care, ongoing trials continue to refine which drug combinations work best, what doses are optimal, and which patients are most likely to benefit.

Research continues into optimizing targeted therapies like bevacizumab and erlotinib for vulvar cancer. Studies may explore different dosing schedules, combinations with other drugs, or ways to identify which patients’ tumors are most likely to respond to these treatments. Some research examines whether testing tumors for specific molecular markers can help predict which targeted therapies will be most effective.

For patients interested in participating in clinical trials, the location and availability of studies can vary. Trials may be conducted at major cancer centers in North America, Europe, and other regions. Eligibility for clinical trials typically depends on factors such as the stage and location of the recurrent cancer, previous treatments received, overall health status, and specific characteristics of the tumor. Patients can discuss clinical trial options with their oncology team or search clinical trial databases to find studies that might be appropriate for their situation.

Most common treatment methods

• Surgery
  • Complete radical vulvectomy—removes the entire vulva, clitoris, deeper tissues under vulvar skin, and nearby lymph nodes
  • Pelvic exenteration—major operation removing vulva, lymph nodes in groin, and one or more pelvic organs (vagina, uterus, bladder, or rectum), typically used for local recurrence in pelvis
  • Type of surgery depends on tumor depth, size, and location
  • May require reconstructive surgery with plastic surgeon consultation
• Radiation therapy
  • External beam radiation therapy—may be used with or without chemotherapy to shrink tumors before surgery or relieve symptoms
  • Brachytherapy—internal radiation placing sealed radioactive container directly into or near tumor, sometimes combined with external radiation
  • Use may be limited if patient already received radiation during initial treatment
• Chemotherapy
  • Often given together with radiation therapy rather than alone
  • Common drug combinations include cisplatin with paclitaxel, or carboplatin with paclitaxel
  • May be used alone as palliative treatment to relieve pain and control symptoms in advanced disease
• Chemoradiation
  • Combination of radiation therapy and chemotherapy given during the same time period
  • May be offered when surgery cannot be performed due to health problems
  • Chemotherapy makes cancer cells more sensitive to radiation
• Targeted therapy
  • Bevacizumab (Avastin and biosimilars)—blocks VEGF protein to cut off tumor blood supply
  • Erlotinib (Tarceva)—targets EGFR protein involved in cell growth
  • Sometimes combined with chemotherapy drugs
  • May not be covered by all health insurance plans